ProCE Banner Activity


Medical Minute 3 – Conventional and New Therapies for Primary Hyperoxaluria Type 1


An expert discussion of conventional and emerging therapy for primary hyperoxaluria (PH), including the use of RNAi treatment and how to manage patients progressing to chronic kidney disease. 

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Released: January 16, 2024

Expiration: January 15, 2025



John C. Lieske

John C. Lieske, MD

Professor of Medicine
Mayo Clinic
Division of Nephrology and Hypertension
Rochester, Minnesota

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Novo Nordisk.

Novo Nordisk

Target Audience

This program is designed to educate nephrologists, pediatricians, urologists, nurse practitioners, physician associates, and other HCPs who manage patients with recurrent kidney stones as well as possible or diagnosed primary hyperoxaluria.

Program Learning Goal

The goal of this educational curriculum is to improve the knowledge and competence of nephrologists, pediatricians, and urologists on primary hyperoxaluria to enhance awareness, timely diagnostic evaluation, and optimize treatment for patients with primary hyperoxaluria type 1.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Construct a treatment plan for a patient with PH1 considering patient-specific genetic, biochemical, and clinical parameters


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

John C. Lieske, MD

Professor of Medicine
Mayo Clinic
Division of Nephrology and Hypertension
Rochester, Minnesota

John C. Lieske, MD: researcher: Alnylam, BioMarin, Dicerna, Novobiome, Siemens, Synlogic; consultant/advisor/speaker: Alnylam, BioMarin, Bridgebio, Chinook, Dicerna, FederationBio, Intellia, Novobiome, Synlogic.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 16, 2024, through January 15, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 contact hours.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until January 15, 2025. PAs should only claim credit commensurate with the extent of their participation.